Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04098874 · ClinicalTrials.gov registry record · Phase 4
Bupropion for the Prevention of Postpartum Smoking Relapse
A Phase 4 study of Postpartum Smoking Relapse, sponsored by University of Minnesota.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT04098874: Recruiting Phase 4 study of Postpartum Smoking Relapse, sponsored by University of Minnesota.
NCT04098874 is a Phase 4 study of Postpartum Smoking Relapse that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 200 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04098874, a Phase 4 study of Postpartum Smoking Relapse, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This two-arm, double-blind, placebo-controlled randomized clinical trial will enroll pregnant women who quit smoking after learning they were pregnant and are motivated to stay abstinent postpartum. Participants will be randomized to receive extended-release bupropion (active 300mg or placebo once daily beginning 4 to 10 days postpartum to 12 weeks post-randomization). All participants will complete the same data collection procedures (e.g., biological sample collection for hormone and cotinine analysis and completion of validated questionnaires) at baseline (gestational week 36), weekly from 4 to 10 days postpartum through 12 weeks post-randomization and at weeks 12, 24, 36 and 52 post-randomization.
Primary Outcome
7-day point prevalence abstinence
Conditions Studied
Interventions
- DRUG Placebo oral tablet
- DRUG Bupropion Extended Release Oral Tablet
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 4 |
What NCT04098874 shows while recruiting
NCT04098874 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Postpartum Smoking Relapse appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04098874 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04098874 about?
NCT04098874 is a clinical study titled "Bupropion for the Prevention of Postpartum Smoking Relapse". This two-arm, double-blind, placebo-controlled randomized clinical trial will enroll pregnant women who quit smoking after learning they were pregnant and are motivated to stay abstinent postpartum. Participants will be randomized to receive extended-release bupropion (active 300mg or placebo once d...
What is the current status of trial NCT04098874?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2020-01-01. Estimated completion is 2026-07-31.
What conditions does trial NCT04098874 study?
This clinical trial studies the following conditions: Postpartum Smoking Relapse.
What interventions are being tested in trial NCT04098874?
The interventions under investigation include: Placebo oral tablet (DRUG), Bupropion Extended Release Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04098874?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04098874 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04098874's enrollment target sits among peer trials
200 407th of 2000 higher than 1,557 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI